0 162

Cited 3 times in

A phase II study of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin (ESHAOx) for patients with refractory or relapsed Hodgkin's lymphoma

DC Field Value Language
dc.contributor.author김진석-
dc.contributor.author이혜원-
dc.date.accessioned2022-09-06T06:37:43Z-
dc.date.available2022-09-06T06:37:43Z-
dc.date.issued2020-02-
dc.identifier.issn0939-5555-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/190235-
dc.description.abstractWe assessed the efficacy and toxicity of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin (ESHAOx) combination chemotherapy in patients with refractory or relapsed Hodgkin's lymphoma (HL). This was an open-label, non-randomized, multi-center phase II study. The ESHAOx regimen consisted of intravenous (i.v.) etoposide 40 mg/m(2) on days 1 to 4, i.v. methylprednisolone 500 mg on days 1 to 5, i.v. cytarabine 2 g/m(2) on day 5, and i.v. oxaliplatin 130 mg/m(2) on day 1. Cycles (up to six) were repeated every 3 weeks. In an effort to identify prognostic markers, the serum levels of cytokines including tumor necrosis factor-alpha (TNF-alpha), C-reactive protein (CRP), and vascular endothelial growth factor (VEGF) were measured at the time of study entry. A total of 37 patients were enrolled, and 36 were available for evaluation of tumor response. The overall response rate was 72.2% (26/36) (complete response, 33.3% [12/36]; partial response, 38.9% [14/36]). The median time to progression was 34.9 months (95% confidence interval, 23.1-46.7 months). The most common grade 3 or 4 hematological adverse events were neutropenia (16/37, 43.2%), followed by thrombocytopenia (10/37, 27.0%). Grade 3 or 4 non-hematological adverse events were nausea (3/37, 8.1%), anorexia (2/37, 5.4%), mucositis (1/37, 2.7%), and skin rash (1/37, 2.7%). There were no treatment-related deaths. High levels of TNF-alpha and CRP were significantly associated with poorer overall survival (p = 0.00005 for TNF-alpha, p = 0.0004 for CRP, respectively). The ESHAOx regimen exhibited antitumor activity and an acceptable safety profile in patients with refractory or relapsed HL.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherSpringer International-
dc.relation.isPartOfANNALS OF HEMATOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols / administration & dosage*-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols / adverse effects-
dc.subject.MESHC-Reactive Protein / metabolism-
dc.subject.MESHCytarabine / administration & dosage-
dc.subject.MESHCytarabine / adverse effects-
dc.subject.MESHDisease-Free Survival-
dc.subject.MESHEtoposide / administration & dosage-
dc.subject.MESHEtoposide / adverse effects-
dc.subject.MESHFemale-
dc.subject.MESHHodgkin Disease* / blood-
dc.subject.MESHHodgkin Disease* / drug therapy-
dc.subject.MESHHodgkin Disease* / mortality-
dc.subject.MESHHumans-
dc.subject.MESHMale-
dc.subject.MESHMethylprednisolone / administration & dosage-
dc.subject.MESHMethylprednisolone / adverse effects-
dc.subject.MESHMiddle Aged-
dc.subject.MESHNeoplasm Proteins / blood*-
dc.subject.MESHOxaliplatin / administration & dosage-
dc.subject.MESHOxaliplatin / adverse effects-
dc.subject.MESHRecurrence-
dc.subject.MESHSurvival Rate-
dc.subject.MESHTime Factors-
dc.subject.MESHTumor Necrosis Factor-alpha / blood-
dc.subject.MESHVascular Endothelial Growth Factor A / blood-
dc.titleA phase II study of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin (ESHAOx) for patients with refractory or relapsed Hodgkin's lymphoma-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorYoung-Woong Won-
dc.contributor.googleauthorHyewon Lee-
dc.contributor.googleauthorHyeon-Seok Eom-
dc.contributor.googleauthorJin Seok Kim-
dc.contributor.googleauthorCheolwon Suh-
dc.contributor.googleauthorDok Hyun Yoon-
dc.contributor.googleauthorJung Yong Hong-
dc.contributor.googleauthorHye Jin Kang-
dc.contributor.googleauthorJae Hoon Lee-
dc.contributor.googleauthorWon Seog Kim-
dc.contributor.googleauthorSeok Jin Kim-
dc.contributor.googleauthorWon-Sik Lee-
dc.contributor.googleauthorMyung Hee Chang-
dc.contributor.googleauthorYoung Rok Do-
dc.contributor.googleauthorJun Ho Yi-
dc.contributor.googleauthorInho Kim-
dc.contributor.googleauthorJong-Ho Won-
dc.contributor.googleauthorKyoungha Kim-
dc.contributor.googleauthorSung Yong Oh-
dc.contributor.googleauthorJae-Cheol Jo-
dc.identifier.doi10.1007/s00277-019-03891-9-
dc.contributor.localIdA01017-
dc.contributor.localIdA03318-
dc.relation.journalcodeJ00161-
dc.identifier.eissn1432-0584-
dc.identifier.pmid31897676-
dc.identifier.urlhttps://link.springer.com/article/10.1007/s00277-019-03891-9-
dc.subject.keywordEtoposide-
dc.subject.keywordMethylprednisolone-
dc.subject.keywordCytarabine-
dc.subject.keywordOxaliplatin-
dc.subject.keywordHodgkin's lymphoma-
dc.contributor.alternativeNameKim, Jin Seok-
dc.contributor.affiliatedAuthor김진석-
dc.contributor.affiliatedAuthor이혜원-
dc.citation.volume99-
dc.citation.number2-
dc.citation.startPage255-
dc.citation.endPage264-
dc.identifier.bibliographicCitationANNALS OF HEMATOLOGY, Vol.99(2) : 255-264, 2020-02-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.